Viralgen is a contract development and manufacturing organization (CDMO) dedicated to adeno-associated virus (AAV) vectors for gene therapy, offering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial cGMP manufacturing. It was launched in 2017 as a joint venture between US gene therapy company AskBio and Spanish life-sciences VC Columbus Venture Partners, with backing from the Basque Government, and operates what it describes as the world's largest AAV-dedicated facility in San Sebastián, Spain, with 400+ employees and 50+ gene therapy customers. It is headquartered in San Sebastián (Basque Country) and has been part of Bayer AG since Bayer acquired AskBio and the remaining Viralgen stake in 2020.
Venture-backed contract biomanufacturer whose gene therapy work includes viral-vector development and cGMP production for drug developers, sold on a fee-for-service basis.
Contract manufacturer for cell and gene therapies offering development, plasmid and large-scale cGMP viral-vector (including AAV) manufacturing to therapy developers.
Contract manufacturer focused on AAV gene therapy with its own large cGMP facility, covering plasmid through clinical and commercial vector supply before Ajinomoto bought it.
Contract manufacturer specialising in AAV and plasmid production, taking gene therapy clients from research-grade vectors to cGMP clinical manufacturing.
V
R
C
F
P
G
A
B